CEO Executive AssistantBiotech CEOs occupy one of the most demanding executive roles in any industry. They are simultaneously responsible for scientific strategy, clinical development oversight, regulatory navigation, business development, investor relations, team building, and organizational management. Many of them are also deeply technical scientists who feel the pull of returning to the scientific work they know best.
The result is a CEO function that is chronically overloaded, where the volume and variety of demands make it nearly impossible to do any single domain of work as well as it deserves. The answer to this structural problem is not working more hours. It is building a leadership team capable of owning significant organizational domains and then actually delegating those domains.
This article identifies the specific functions and decision categories that biotech CEOs should delegate to their leadership teams, organized by the leadership role most appropriate to receive each delegation.
Delegate Scientific Program Execution to the CSO
The Chief Scientific Officer should own the full scientific execution of the company’s research programs. This delegation is particularly difficult for biotech CEOs with scientific backgrounds who built their reputation on scientific insight and who may be better scientists than their CSO.
The discipline of delegation here requires the CEO to accept that excellent scientific execution managed by the CSO, even if slightly different from how the CEO would personally approach the science, is better for the organization than adequate scientific execution managed personally by an over-extended CEO.
Specifically delegate to the CSO:
- All research program design and experimental strategy decisions
- Scientific team hiring and management
- Research vendor and CRO relationships for preclinical work
- Scientific Advisory Board meeting preparation and agenda
- Platform technology development strategy
- Publication strategy for research-stage findings
The CEO should receive monthly scientific updates, participate in quarterly scientific reviews, and make strategic portfolio decisions based on CSO recommendation. The CEO should not be attending laboratory team meetings, reviewing experimental protocols, or making experimental design decisions.
Delegate Clinical Program Management to the CMO
The Chief Medical Officer should own the full clinical operations of all programs in clinical development. This is the delegation that most biotech CEOs struggle with most acutely, because the clinical milestones are the most investor-visible events in the company’s calendar and the stakes of clinical failure are existential for early-stage companies.
The intensity of clinical program milestones is precisely why the CMO delegation must be clean. A clinical program that has a CMO who operates with clear authority to manage the program efficiently will advance faster and more effectively than one where every operational decision requires CEO consultation.
Specifically delegate to the CMO:
- Protocol design and amendment management
- Investigator site selection and management
- CRO selection and management within approved budget
- DSMB management and safety review processes
- FDA meeting preparation and primary FDA relationship management
- Clinical team management and staffing
- Enrollment strategy and site activation
The CEO engages with clinical programs at: program steering committee meetings (quarterly), significant data readouts, FDA meeting attendance where CEO presence is strategic, and all investor-related clinical communications. Everything between these touchpoints is the CMO’s domain.
Delegate Regulatory Strategy Execution to the Head of Regulatory
Regulatory affairs in a biotech company involves a specialized blend of scientific, legal, and strategic expertise that most biotech CEOs do not have depth in. The Head of Regulatory Affairs should own the full regulatory strategy and execution for each program.
Specifically delegate to the Head of Regulatory:
- IND preparation and maintenance
- FDA correspondence and response management
- Regulatory strategy development for each program
- Regulatory Agency meetings (preparation, primary contact, follow-up)
- Label strategy as programs advance to NDA stage
- International regulatory strategy
The CEO reviews and approves regulatory strategy at defined strategic moments, participates in high-profile FDA meetings where CEO presence signals organizational commitment, and receives a monthly regulatory update covering the status of all active regulatory activities.
For context on how regulatory delegation connects to the clinical operations structure, see pharma CEO clinical ops, which provides a comprehensive framework for delegating across clinical and regulatory functions.
Delegate Commercial Operations to the CCO
For biotechs with marketed products or approaching commercialization, the Chief Commercial Officer should own the full commercial execution. This delegation requires that the biotech CEO resist the temptation to substitute scientific product knowledge for commercial judgment.
Specifically delegate to the CCO:
- Brand strategy and promotional execution
- Sales force deployment and management
- Market access and payer strategy
- Commercial launch planning and execution
- Commercial analytics and forecasting
- Commercial team hiring and management
The CEO’s commercial role is: approving the commercial strategy, representing commercial performance to investors and the board, engaging with the most strategic customer and partner relationships, and providing scientific credibility in commercial contexts where CEO scientific background is an asset.
Delegate Finance and Administration to the CFO
The Chief Financial Officer should own the full financial management of the company: financial reporting, financial controls, investor financial communications, capital allocation analysis, audit management, and financial compliance. The CEO should not be managing the books or reviewing individual financial transactions.
Specifically delegate to the CFO:
- Financial reporting preparation
- Investor financial communications content (CEO delivers, CFO prepares)
- Audit management
- Cash management within board-approved parameters
- Financial forecasting and modeling
- Budget management and reporting
The CEO participates in quarterly investor calls, reviews monthly financial dashboards, approves the annual budget, and makes strategic capital allocation decisions with CFO recommendation. Everything else is the CFO’s domain.
Delegate Business Development Execution to the Head of BD
Business development, including partnership discussions, licensing negotiations, and M&A activity, involves both strategic judgment (CEO domain) and operational execution (BD function domain). Delegating the execution while retaining the strategy is the appropriate division for most biotechs.
Specifically delegate to the Head of Business Development:
- Screening and evaluating potential deals
- Managing due diligence processes
- Leading term sheet and contract negotiations (except the final CEO-to-CEO conversation)
- Managing the business development pipeline
- Building and managing BD network relationships
The CEO engages for: the initial strategic conversation with a potential partner or target, the final deal terms negotiation at the CEO level, board presentations about major transactions, and investor communication about business development.
Delegate People and Culture Operations to the CHRO
Human resources operations, including recruiting, onboarding, benefits, performance management, and compliance, should be owned by the Chief Human Resources Officer or Head of People. The CEO’s people role is culture-setting and senior team development, not HR administration.
Specifically delegate to the CHRO:
- Recruiting process for all positions
- Compensation administration within approved frameworks
- Benefits management
- Performance review process management
- Compliance with employment regulations
- HR systems and analytics
The CEO retains: final hiring decisions for VP-level and above, annual compensation strategy approval, senior leadership development, and cultural leadership through behaviors and communications.
Delegate Operations and Infrastructure to the COO
For biotechs with significant operational complexity, a Chief Operating Officer should own: facility management, information technology infrastructure, procurement, supply chain, and general administration. These operational functions rarely require CEO expertise or judgment.
Specifically delegate to the COO:
- Facility management and expansion decisions within approved budget
- IT infrastructure and systems
- Procurement policy and major vendor relationships
- Supply chain management
- Operational budget management
The CEO approves major capital investments and strategic operational decisions. Everything operational below that threshold belongs to the COO.
Building the Leadership Team for These Delegations
The prerequisite for all of these delegations is having a leadership team capable of receiving them. A CSO who cannot manage the research function independently, a CMO who lacks the judgment to run clinical programs without constant CEO input, or a CCO who has not run a pharma commercial organization before will naturally require more CEO involvement.
Investing in leadership team quality, either by hiring highly experienced functional leaders or by developing internal candidates with appropriate support and coaching, is the prerequisite investment that makes delegation work.
According to McKinsey research on biotech organizational effectiveness, biotech companies with strong functional leadership teams significantly outperform those with centralized, CEO-dependent decision-making. The delegation list above is the organizational architecture that enables this performance difference.
See pharma CEO delegation guide for a comprehensive view of how biotech CEO delegation across all leadership functions creates the organizational capacity for scientific and commercial excellence.
The CEO After Full Leadership Team Delegation
What remains for the CEO after these delegations? The work that only the CEO can do: setting the scientific and commercial strategy that aligns the whole organization, building the board into a strong governance and support body, cultivating the investor relationships that fund the company’s ambitions, managing the most significant external partnerships, and stewarding the organizational culture that attracts and retains the talent these delegations depend on.
This is not less work. It is more important work, work that has longer time horizons and higher organizational leverage than any of the functional domains listed above. The biotech CEO who builds a delegation structure that frees them for this work is building the organizational foundation for sustained scientific and commercial achievement.
Related Reading
For further context, explore What Biotech CEOs Delegate During Phase 3 Trials and Automotive CEO Delegation for Aftermarket and Parts.